NetworkNewsBreaks – Pressure BioSciences, Inc. (
Post# of 1354
(Total Views: 138)
Posted On: 10/18/2017 7:26:01 PM
NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Enters Collaboration Agreement with Phasex Corporation
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the worldwide life sciences industry, this morning announced a collaboration with Phasex Corporation, one of the world’s most experienced supercritical fluid (“SCF”)-based toll processors. The goal of the collaboration is to combine PBI’s recently patented Ultra Shear Technology with Phasex’s SCF-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. “Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies,” Richard T. Schumacher, president and CEO of PBI, stated in the news release. “Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the worldwide life sciences industry, this morning announced a collaboration with Phasex Corporation, one of the world’s most experienced supercritical fluid (“SCF”)-based toll processors. The goal of the collaboration is to combine PBI’s recently patented Ultra Shear Technology with Phasex’s SCF-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. “Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies,” Richard T. Schumacher, president and CEO of PBI, stated in the news release. “Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼